Clinical Trial Update: A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032 [Phase 2]

View source ↗

Summary

Long-term safety data from a Phase 2 study of BI 655130 in patients with atopic dermatitis; the trial was terminated and results were posted in May 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BI 655130

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Dermatitis, Atopic | Phase 2 | Status: TERMINATED | Results posted: 2022-05-18